Bosutinib is active in chronic phase chronic myeloid leukemia after imatinib and dasatinib and/or nilotinib therapy failure.

HJ, Khoury; JE, Cortes; HM, Kantarjian; C, Gambacorti-Passerini; M, Baccarani; DW, Kim; A, Zaritskey; A, Countouriotis; N, Besson; E, Leip; V, Kelly; TH, Brümmendorf

doi:10.1182/blood-2011-11-390120

Public

Bosutinib is active in chronic phase chronic myeloid leukemia after imatinib and dasatinib and/or nilotinib therapy failure.

Shared by NobleBlocks on Feb 27, 2012 • 12:00 AM UTC

Authors:

Khoury HJ

Cortes JE

Kantarjian HM

Abstract

Bosutinib, a dual Src/Abl tyrosine kinase inhibitor (TKI), has shown potent activity against chronic myeloid leukemia (CML). This phase 1/2 study evaluated the efficacy and safety of once-daily bosutinib 500 mg in leukemia patients after resistance/intolerance to imatinib. The current analysis inclu...

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!